Combination therapy of vaccinia virus infection with human anti-H3 and anti-B5 monoclonal antibodies in a small animal model.
Combination therapy of vaccinia virus infection with human anti-H3 and anti-B5 monoclonal antibodies in a small animal model.
复制标题
DOI：
10.3851/imp1573
复制
发表时间：
2010
影响因子：
1.2
通讯作者：
Crotty S
中科院分区：
文献类型：
--
作者：
McCausland MM;Benhnia MR;Crickard L;Laudenslager J;Granger SW;Tahara T;Kubo R;Koriazova L;Kato S;Crotty S
痘苗病毒在体内具有两种免疫学上不同的病毒体形式-成熟病毒体（MV，IMV）和细胞外病毒体（EV，EEV）。在这里，我们表明，在进行性牛痘的小动物模型中，用针对免疫显性MV抗原H3（H3 L）和EV抗原B5（B5 R）的两种完全人源mAb的联合治疗提供了显著更好的针对牛痘感染的保护（用VACVNYCBOH疫苗株感染的SCID小鼠）比单一人单克隆或人牛痘免疫球蛋白（VIG），目前批准的治疗天花疫苗副作用的药物。
Vaccinia virus possesses two immunologically distinct virion forms in vivo—mature virion (MV, IMV) and extracellular virion (EV, EEV). Here we show that combination therapy with two fully human mAbs against an immunodominant MV antigen, H3 (H3L), and an EV antigen, B5 (B5R), provides significantly better protection against vaccinia infection in a small animal model of progressive vaccinia (SCID mice infected with VACVNYCBOH vaccine strain) than a single human monoclonal or human vaccinia immune globulin (VIG), the currently licensed therapeutic for side effects of smallpox vaccination.